Drug Shortage Report for MYLAN-ZOLMITRIPTAN ODT
| Report ID | 17818 |
| Drug Identification Number | 02387158 |
| Brand name | MYLAN-ZOLMITRIPTAN ODT |
| Common or Proper name | ZOLMITRIPTAN ODT |
| Company Name | MYLAN PHARMACEUTICALS ULC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | ZOLMITRIPTAN |
| Strength(s) | 2.5MG |
| Dosage form(s) | TABLET (ORALLY DISINTEGRATING) |
| Route of administration | ORAL |
| Packaging size | 6BL |
| ATC code | N02CC |
| ATC description | ANTIMIGRAINE PREPARATIONS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2018-06-22 |
| Actual start date | 2018-07-03 |
| Estimated end date | Unknown |
| Actual end date | 2018-07-03 |
| Shortage status | Resolved |
| Updated date | 2018-07-05 |
| Company comments | Discontinued in ID 51653 |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
| Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v52 | 2018-07-05 | French | Compare |
| v51 | 2018-07-05 | English | Compare |
| v50 | 2018-07-04 | English | Compare |
| v49 | 2018-07-03 | French | Compare |
| v48 | 2018-07-03 | English | Compare |
| v47 | 2018-07-03 | French | Compare |
| v46 | 2018-07-03 | English | Compare |
| v45 | 2018-06-23 | English | Compare |
| v44 | 2018-06-06 | French | Compare |
| v43 | 2018-06-06 | English | Compare |
| v42 | 2018-02-28 | English | Compare |
| v41 | 2018-02-27 | French | Compare |
| v40 | 2018-02-27 | English | Compare |
| v39 | 2018-02-23 | French | Compare |
| v38 | 2018-02-23 | English | Compare |
| v37 | 2018-02-02 | French | Compare |
| v36 | 2018-02-02 | English | Compare |
| v35 | 2018-01-22 | French | Compare |
| v34 | 2018-01-22 | English | Compare |
| v33 | 2018-01-08 | French | Compare |